Brought to you by 
Zai Lab completes $160mm US IPO
18 Oct 2017
Executive Summary
Chinese drug developer Zai Labs Ltd. completed its initial public offering in the US, netting $160mm through the sale of 9.58mm American Depositary Shares (including the overallotment; representing 9.58mm common) at $18 per ADS. Earlier this month, the company stated that it hoped to sell 5.88mm ADSs at a range of $16-18.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Zai Lab completes $160mm US IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice